doi: 10.1161/01.RES.0000255897.84337.38
© 2007 American Heart Association, Inc.
Editorials |
A Novel Application for Murine Double Minute 2 Antagonists
The p53 Tumor Suppressor Network Also Controls Angiogenesis
From the Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University Vienna.
Correspondence to Bernd R. Binder, Department of Vascular Biology and Thrombosis Research, Center for Biomolecular Medicine and Pharmacology, Medical University Vienna, Schwarzspanierstr. 17, 1090, Austria. E-mail bernd.binder{at}meduniwien.ac.at
Key Words: angiogenesis • MDM2 • p53 • nutlin-3
Impairment of the p53 tumor suppressor network1 is thought to be involved in a large percentage of tumors either by mutations in the p53 gene2–4 or by increased expression of its major control system, the MDM25 (murine double minute 2; HDM2 for its human equivalent). It is important to realize that levels of p53 are subjected to an autoregulatory feedback loop by MDM26,7 as p53 upregulates MDM2 gene expression and MDM2 protein in turn binds to p53. MDM2 is an E3 ubiquitin ligase and transports p53 to the cytoplasm where it promotes p53 ubiquitination and degradation by the proteasome. In human cancer, increased levels of MDM26 are caused either by gene amplification, increased expression induced by activated p53, stabilization by an aberrantly spliced form of HMDX8, or augmented translation. In addition to these mechanisms, functional single-nucleotide polymorphisms (SNP) such as the 1 at nucleotide 309 (SNP309) in the MDM2 gene can modulate MDM2 expression and cause increased tumor progression.9 Thus, mutations in the p53 gene or an increase in MDM2 protein impair the effectiveness of p53-dependent proapoptotic and cell-cycle arrest mechanisms and thereby favor the development of tumors. In addition, MDM2 has also p53-independent activities10,11 through interactions with proteins involved in controlling cell proliferation and survival. This concatenation of data indicated that disruption of the p53–MDM2 autoregulatory feedback loop as well as inhibition of MDM2 would be a suitable strategy for tumor therapy. In fact, Vassilev et al12 recently developed a class of small molecules, the nutlins (eg, nutlin-3, a tetra-substituted imidazoline), that occupy the p53-binding pocket in MDM213 thereby preventing MDM2 binding to p53. Similarly, nutlin-3 also binds to and interferes with MDMX,14 another component of the p53 tumor surveillance pathway. This leads to a disruption of the autoregulatory feedback loop and consequently the p53 tumor suppressor network is fostered. Consistently, Vassilev et al further showed that nutlin-3 induces apoptosis especially in cancer cell lines with increased MDM2 expression15 which correlates well with in vivo antitumor efficacy of nutlin-3 (Figure 1).
|
An antitumor strategy that interferes with the p53 – MDM2 feedback loop should therefore work best in tumors with wild type p53 (approximately 
50% of all tumors) and increased MDM2 which suppresses functional active p53. On the other hand, such a strategy does not appear to be promising in tumors with a mutated p53 gene. In this issue of Circulation Research, Secchiero et al,16 however, report that nutlin-3 may have additional potent antitumor activities by a novel effect of this molecule on angiogenesis. This antiangiogenic effect of nutlin-3 might be an important widening of the possible therapeutic window for nutlin-3 as it is assumed that endothelial cells of blood vessels supplying even a tumor with mutations in p53 do in general not contain such p53 mutations. It is now clear that tumor growth and progression critically depend on an adequate blood supply.17,18 Moreover, antiangiogenic therapies have the advantage of not inducing tumor resistance. Thus, a nutlin-3 based antitumor therapy might also have potential in tumors containing a mutated and nonfunctioning p53 gene.
What are the underlying mechanisms for the anti-angiogenic activity of nutlin-3? In this article the authors demonstrate that nutlin-3 has antiangiogenic activities via 3 different mechanisms: (1) by inhibiting endothelial cell migration, which seems to be the predominant effect; (2) by inducing cell cycle arrest; and (3) by increasing apoptotic tendency in endothelial cells. The authors also show that nutlin-3 treatment of endothelial cells leads to accumulation of p53, indicating that the effects of nutlin-3 in these cells are also related to its interference with the p53–MDM2 autoregulatory feedback loop (Figure 2). There are only few reports of a direct effect of p53 in endothelial cells.19 However, with respect to tumor cell migration an effect of p53 on cell motility has been demonstrated which is largely mediated through the regulation of Rho signaling, thereby controlling actin cytoskeletal organization (reviewed in20). One could speculate that in analogy to tumor cells a similar mechanism might be responsible for the effects in endothelial cells.
|
The data presented here by Secchiero et al are far from clinical applications and even the in vivo data are restricted to a Matrigel plug system in mice. Nevertheless, these data might open a new route for a broader application of nutlin-3 or other MDM2 antagonists7,21,22 not only for direct antitumor therapies but also for application in antiangiogenic regimens.23
 |
Acknowledgments |
|---|
Source of Funding
Supported partially by the EU 6th framework program EVGN (contract number LSHM-CT-2003–503254) and the EU 6th Framework Integrated Project Cancerdegradome (LSHC-CT-2003–503297).
Disclosures
None.
|
Footnotes |
|---|
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
|
References |
|---|
 Top References |
|---|
1. Lowe SW, Cepero E, Evan G. Intrinsic tumour suppression. Nature. 2004; 432: 307–315.[CrossRef][Medline] [Order article via Infotrieve]
2. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science. 1991; 253: 49–53.
3. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res. 2000; 77: 81–137.[Medline] [Order article via Infotrieve]
4. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408: 307–310.[CrossRef][Medline] [Order article via Infotrieve]
5. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998; 26: 3453–3459.
6. Bond GL, Hu W, Levine AJ. MDM2 is a central node in the p53 pathway: 12 years and counting. Curr Cancer Drug Targets. 2005; 5: 3–8.[CrossRef][Medline] [Order article via Infotrieve]
7. Fischer PM, Lane DP. Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol Sci. 2004; 25: 343–346.[CrossRef][Medline] [Order article via Infotrieve]
8. Giglio S, Mancini F, Gentiletti F, Sparaco G, Felicioni L, Barassi F, Martella C, Prodosmo A, Iacovelli S, Buttitta F, Farsetti A, Soddu S, Marchetti A, Sacchi A, Pontecorvi A, Moretti F. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization. Cancer Res. 2005; 65: 9687–9694.
9. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, Onel K, Yip L, Hwang SJ, Strong LC, Lozano G, Levine AJ. A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell. 2004; 119: 591–602.[CrossRef][Medline] [Order article via Infotrieve]
10. Zhang Z, Zhang R. p53-independent activities of MDM2 and their relevance to cancer therapy. Curr Cancer Drug Targets. 2005; 5: 9–20.[CrossRef][Medline] [Order article via Infotrieve]
11. Jones SN, Hancock AR, Vogel H, Donehower LA, Bradley A. Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998; 95: 15608–15612.
12. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, Kong N, Kammlott U, Lukacs C, Klein C, Fotouhi N, Liu EA. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science. 2004; 303: 844–848.
13. Kussie PH, Gorina S, Marechal V, Elenbaas B, Moreau J, Levine AJ, Pavletich NP. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science. 1996; 274: 948–953.
14. Laurie NA, Donovan SL, Shih CS, Zhang J, Mills N, Fuller C, Teunisse A, Lam S, Ramos Y, Mohan A, Johnson D, Wilson M, Rodriguez-Galindo C, Quarto M, Francoz S, Mendrysa SM, Guy RK, Marine JC, Jochemsen AG, Dyer MA. Inactivation of the p53 pathway in retinoblastoma. Nature. 2006; 444: 61–66.[CrossRef][Medline] [Order article via Infotrieve]
15. Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu BT, Qing W, Packman K, Myklebost O, Heimbrook DC, Vassilev LT. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci U S A. 2006; 103: 1888–1893.
16. Secchiero P, Corallini F, Gonelli A, Dell’eva R, Vitale M, Capitani S, Albini A, Zauli G. Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3. Circ Res. 2007; 100: 61–69.
17. Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003; 9: 653–660.[CrossRef][Medline] [Order article via Infotrieve]
18. Folkman J. Angiogenesis-dependent diseases. Semin Oncol. 2001; 28: 536–542.[CrossRef][Medline] [Order article via Infotrieve]
19. Yeh JR, Mohan R, Crews CM. The antiangiogenic agent TNP-470 requires p53 and p21CIP/WAF for endothelial cell growth arrest. Proc Natl Acad Sci U S A. 2000; 97: 12782–12787.
20. Roger L, Gadea G, Roux P. Control of cell migration: a tumour suppressor function for p53? Biol Cell. 2006; 98: 141–152.[Medline] [Order article via Infotrieve]
21. Vassilev LT. p53 Activation by small molecules: application in oncology. J Med Chem. 2005; 48: 4491–4499.[CrossRef][Medline] [Order article via Infotrieve]
22. Fotouhi N, Graves B. Small molecule inhibitors of p53/MDM2 interaction. Curr Top Med Chem. 2005; 5: 159–165.[CrossRef][Medline] [Order article via Infotrieve]
23. Zhong X, Li X, Wang G, Zhu Y, Hu G, Zhao J, Neace C, Ding H, Reed E, Li QQ. Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. Int J Oncol. 2004; 25: 445–451.[Medline] [Order article via Infotrieve]
24. Harris CC. Protein-protein interactions for cancer therapy. Proc Natl Acad Sci U S A. 2006; 103: 1659–1660.
This article has been cited by other articles:
 |
|
 |
|
  Y.-M. Lee, J.-H. Lim, Y.-S. Chun, H.-E. Moon, M. K. Lee, L.E. Huang, and J.-W. Park Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1{alpha} Carcinogenesis, October 1, 2009; 30(10): 1768 - 1775. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Shangary and S. Wang Targeting the MDM2-p53 Interaction for Cancer Therapy Clin. Cancer Res., September 1, 2008; 14(17): 5318 - 5324. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||